Quick Answer
AYTU BIOPHARMA, INC reported Diluted EPS of $5.11 per share (loss) for fiscal year 2023.
AYTU BIOPHARMA, INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$5.11 | +93.1% |
| 2022 | -$74.01 | -2026.7% |
| 2021 | -$3.48 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$1.05 | -303.8% | -1212.5% |
| September 30, 2025 | -$0.08 | +46.7% | -138.1% |
| March 31, 2025 | $0.21 | +140.4% | +180.8% |
| December 31, 2024 | -$0.26 | -550.0% | -73.3% |
| September 30, 2024 | -$0.15 | +89.9% | +71.2% |
| March 31, 2024 | -$0.52 | +73.1% | -1200.0% |
| December 31, 2023 | -$0.04 | +98.1% | +97.3% |
| September 30, 2023 | -$1.48 | -428.6% | +23.3% |
- AYTU BIOPHARMA, INC showed an increase of +93.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2023 period, AYTU BIOPHARMA, INC’s diluted eps has declined by 46.8% (from $3.48 per share (loss) to $5.11 per share (loss)).
- The most recent figure is from AYTU BIOPHARMA, INC’s fiscal year 2023 report (Form 10-K), filed with the SEC on October 12, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: